87 results about "Intraperitoneal route" patented technology

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for improving hypoxia resistance of pelteobagrus vachelli based on hypoxia induction of liver extracellular vesicles of the pelteobagrus vachelli. The method comprises the following steps: extracting high-purity extracellular vesicles EVs in liver tissues of pelteobagrus vachelli subjected to low-oxygen treatment by adopting a method of combining differential centrifugation and high-precision iodixanol density gradient centrifugation; diluting the extracted EVs to 2mu g / mu L by using PBS (Phosphate Buffer Solution) to prepare an EVs suspension; an intraperitoneal injection mode is adopted, the EVs suspension is injected into the body of the pelteobagrus vachelli, and after injection is conducted for 24 hours, the hypoxia resistance of the pelteobagrus vachelli is evaluated through a suffocation point detection test. The invention opens up a brand new path for improving the hypoxia resistance of the pelteobagrus vachelli, provides a new idea and a new method for efficiently enhancing the hypoxia resistance of economic fishes in the field of aquaculture, is expected to play an important role in actual aquaculture production, and assists the sustainable development of the aquaculture industry.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention relates to the technical field of laboratory devices, in particular to an intelligent intraperitoneal injection auxiliary fixing device for laboratory mice, which comprises a basic bearing module, and a mouse fixing module, a pressure monitoring module, a control module, an indication module and a power supply module which are mounted on the basic bearing module, wherein the mouse fixing module is used for fixing a mouse, the mouse fixing module comprises a lower arc-shaped latticed clamping plate, an upper arc-shaped clamping plate, a connecting piece and a hook lock, the lower arc-shaped latticed clamping plate and the upper arc-shaped clamping plate are connected through the connecting piece, and the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate are jointly matched to clamp the mouse; the abdomen of the mouse faces the lower arc-shaped latticed clamping plate, the hook lock is used for fixing the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate, the pressure monitoring module can monitor the stress condition of the mouse in real time, compressive stress or suffocation of the mouse is avoided, and animal welfare is improved.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention discloses an application of an LCN2 protein. The application comprises the following applications: a, an application in preparation of a medicine for improving the plasticity of a visual cortex; b, application in preparation of drugs for treating visual cortex injury related diseases; the administration mode of the medicine is peripheral administration. The invention also discloses a peripherally administered LCN2 protein medicine, which comprises the LCN2 protein and a pharmaceutically acceptable carrier or auxiliary material, the peripheral administration of the LCN2 protein drug can improve the plasticity of the visual cortex and can treat visual cortex injury related diseases. According to the invention, the LCN2 protein is taken as an active ingredient, and a peripheral administration mode of intraperitoneal injection is adopted, so that the LCN2 protein can recover the nearly disappeared eye dominant plasticity of an adult individual, and a new way is provided for treating diseases related to visual cortex injury.

The invention discloses application of gaboxadol or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating liver fibrosis diseases, and belongs to the technical field of biological medicines, and research shows that the compound can influence collagen fiber crosslinking through targeted inhibition of the function of prolyl-4-hydroxylase a1 (prolyl-4-hydroxylase alpha 1, P4ha1), so that the anti-fibrosis effect is achieved. The invention further discloses an application of the gaboxadol or the pharmaceutically acceptable salt thereof in preparation of the medicine for treating the liver fibrosis diseases, and the application of the gaboxadol or the pharmaceutically acceptable salt thereof in preparation of the medicine for treating the liver fibrosis diseases and the application of the gaboxadol or the pharmaceutically acceptable salt thereof in preparation of the medicine for treating the liver fibrosis diseases. In a carbon tetrachloride induced mouse hepatic fibrosis model, the content of hydroxyproline and collagen deposition in I-type collagen molecules of the liver can be remarkably reduced by injecting the gaboxadol hydrochloride into the intraperitoneal cavity, and the hardness of the liver is reduced. A surface plasma resonance experiment proves that the probe has specific binding capacity with P4ha1. Toxicity experiments show that the compound is good in safety under the effective dosage. Therefore, the invention provides a new drug candidate and a theoretical basis for the treatment of hepatic fibrosis.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

This invention discloses a live attenuated vaccine for the prevention of Toxoplasma gondii infection, the active ingredient of which is the tachyzoite of the Toxoplasma gondii RHΔpCaBp1 gene knockout strain. This invention prepares a live attenuated RHΔpCaBp1 vaccine that can be used to prevent Toxoplasma gondii infection in intermediate hosts. Immunization with this live attenuated vaccine, containing 100 Toxoplasma gondii RHΔpCaBp1 tachyzoites, via intraperitoneal injection, showed safety in mice after three immunizations, and demonstrated 100% protection against low-dose virulent strains (intraperitoneal injection of 100 and 500 RH tachyzoites) in the model intermediate host.

The invention belongs to the technical field of biological appliances for medical research, and particularly relates to a urinary surgery CP / CPPS model and a modeling method thereof. The modeling method comprises the following steps: (1) preparing prostate homogenate: taking rats of 4 months old, stripping prostate tissues under a sterile condition after the rats are killed, and grinding or homogenizing to prepare an injection suspension; (2) preparing a vaccine intraperitoneal injection: dissolving the inactivated vaccine freeze-dried powder into aluminum hydroxide gel normal saline to prepare the vaccine intraperitoneal injection; (3) injection of molding liquid: after anesthetizing the mouse, subcutaneously injecting prostate homogenate suspension, and intraperitoneally injecting vaccine intraperitoneal injection; and repeating the injection step until the mouse CP / CPPS model is formed. The modeling material disclosed by the invention can be conveniently purchased, the modeling material has common phenotypes of emotional abnormalities such as pain sensitization, anxiety, depression and the like of chronic pain after being molded, the phenotypes after modeling can be maintained for at least 90 days and can exceed half a year at most, the success rate of single-batch modeling is high, and the case fatality rate is low.

The invention discloses an application of a fibroblast growth factor 2 in preparation of a medicine for preventing and / or treating calcium oxalate kidney stone, and breaks through the technical prejudice that FGF-2 mainly promotes renal fibrosis in the prior art. It is found and proved for the first time that exogenous supplement FGF-2 can play a significant therapeutic effect in a calcium oxalate kidney stone model. Animal experiments prove that through intraperitoneal injection of FGF-2 (0.1 mg / kg / day), calcium salt crystal deposition in kidney tissue can be effectively reduced (Von Kossa dyeing verification), structural damage of renal tubular epithelial cells is relieved, inflammatory response is inhibited (HE dyeing verification), and meanwhile the serum creatinine and urea nitrogen level is remarkably improved. The invention provides a brand new molecular target and drug strategy for treatment of kidney stone, can be used as an effective auxiliary scheme of the existing physical lithotripsy technology, and reduces the risk of stone residue and recurrence.

The application provides a method for constructing a mouse model of mitochondrial myopathy with a Lars2 gene deletion and application thereof, a first Lars2 flox / flox mouse is obtained by crossing an Acta1 ER‑Cre mouse with an Acta1 ER‑Cre -Lars2 flox / flox mouse; in the second step, the above mouse reaches 4 weeks of age, and tamoxifen 70-80 mg / kg is used for continuous intraperitoneal injection for 5 days; in the third step, 4 weeks later, tamoxifen 45-55 mg / kg is used for continuous intraperitoneal injection for 5 days; in the fourth step, the Acta1 ER‑Cre -Lars2 flox / flox mouse reaches 12-13 weeks of age, and skeletal muscle Lars2 protein deletion occurs, and skeletal muscle atrophy occurs obviously at 16 weeks of age, thereby obtaining a mouse model of mitochondrial myopathy with a Lars2 gene deletion.

The invention discloses application of ISCA2 in preparation of drugs for preventing and treating peritoneal fibrosis and related products and methods, relates to the technical field of biological medicines, and is characterized in that the application of ISCA2 protein in preparation of drugs for preventing and / or treating peritoneal fibrosis is provided. The invention provides a brand new application of the ISCA2. Experiments prove that the expression of the ISCA2 protein in peritoneal tissues of mice is inhibited in a high-glucose environment, and the activity of the iron-sulfur cluster enzyme can be promoted by injecting the ISCA2 adeno-associated virus into the peritoneal cavity of the mice to over-express the ISCA2 protein, so that the peritoneal fibrosis condition is improved; based on experimental results, it can be known that the overexpressed ISCA2 can play a role in treating peritoneal fibrosis, and therefore the ISCA2 has a good application prospect in the field of preparation of related drugs.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

This invention provides a method for constructing a liver injury model in largemouth bass and its application, belonging to the field of aquatic pharmaceuticals. The construction method includes the following steps: 1) Intraperitoneal injection of thioacetamide into largemouth bass at a dose of 100-150 mg / kg body weight, once; 2) Obtaining the model after 6-15 days of conventional rearing. This invention enables model creation with a short cycle, low cost, good reproducibility, and simple operation, solving the problem of high animal mortality in existing technologies for creating acute liver injury models.

This application discloses the use of ritonavir or its derivatives in the preparation of medicaments for treating mental disorders. This application also discloses the discovery of mice (AtLAS) with difficulty in extinction of fear memories. ‑ / ‑ Intraperitoneal injection of ritonavir significantly restored the rigidity rate in model mice. Further immunoblotting and co-precipitation confirmed that ritonavir could significantly block the binding of Syn2a and Syngr-3, and promote the formation of VAMP2, Syntaxin, and SNAP25 trimers, thereby promoting the normal release of presynaptic membrane vesicles in neurons and restoring the rigidity rate in mice with refractory rigidity, thus achieving the treatment of mental disorders such as post-traumatic stress disorder.

The invention discloses application of chlorogenic acid combined with sivelestat sodium in prevention and treatment of infectious diseases. Through animal in-vivo experiments, the protective effect of chlorogenic acid (CGA) and sivelestat sodium (SIV) on mouse lethality caused by klebsiella pneumoniae (Kpn) infection is verified in a constructed model of sepsis caused by klebsiella pneumoniae infection, the survival rate of infected mice can be increased by combining chlorogenic acid (CGA) and sivelestat sodium (SIV), the weight loss of the mice caused by infection can be resisted, and the curative effect of the sivelestat sodium (SIV) on the mice caused by klebsiella pneumoniae (Kpn) can be improved. Experiments prove that continuous intraperitoneal injection of chlorogenic acid does not cause significant change of hemogram-related indexes, indicating that chlorogenic acid has good safety. According to the scheme of combining the chlorogenic acid with the sivelestat sodium, through the advantages of precise targeted anti-inflammation, two-way immune regulation, anti-infection and immune synergy and the like, the defects of an existing immune regulation technology for bacterial sepsis are comprehensively overcome, and a new optimization direction is provided for clinical treatment.

The invention relates to the field of construction of disease animal models, in particular to a construction method and application of a primary hemophagic syndrome animal model. The model is constructed based on combination of PRF1 gene (perforin 1 gene) knockout mice and lymphochoroidal meningitis virus infection, and typical HLH pathological characteristics are successfully induced in the PRF1 gene knockout mice through single intraperitoneal injection of the lymphochoroidal meningitis virus. Comprise weight loss, continuous fever, pancytopenia, serum ferritin and sCD25 level significant increase and bone marrow blood phagocytosis; compared with an existing CpG ODN1826 repeated injection model, the model has higher genetic specificity and clinical correlation, operation is simplified, cost is reduced, and a standardized experimental platform is provided for pharmacological and pathogenesis research of HLH.

The invention discloses an in-vivo evaluation method for the curative effect of NK cells on human ovarian cancer ascites tumor, which comprises the following steps: inoculating human ovarian cancer cells into the abdominal cavity of a female healthy mouse, and establishing a nude mouse model of the human ovarian cancer ascites tumor; nude mouse models are grouped, and intraperitoneal injection administration is carried out on each group of mice; and carrying out fluorescence tracing on the dosed mouse by adopting a fluorescence imaging method, observing the health and death conditions of the mouse at the same time, and judging the treatment effect of the NK cells on the human ovarian cancer ascites tumor. An ovarian cancer mouse model is established through intraperitoneal injection of an SK-OV-3 cell strain, the treatment effect of NK cells on human ovarian cancer ascites tumor in an in-vivo peritoneal complex environment is evaluated, the result is closer to the actual situation, and the detection result is accurate. The compound is applied to preparation of medicines for treating human ovarian cancer ascites tumor, and can significantly prolong the lifetime, reduce the death rate, reduce the tumor load and improve the life quality.

The invention discloses a method for constructing an animal skin burn model through radio frequency, and the method comprises the following steps: S1, carrying out fasting and water-prohibiting on an experimental animal, carrying out intraperitoneal injection anesthesia by adopting 30mg / kg pentobarbital sodium after fasting and water-prohibiting, removing hair in a back experimental area after anesthesia, and cleaning the experimental area with normal saline; and S2, the radio frequency emission head is tightly attached to the skin of the experimental area on the back of the experimental animal, one emission of radio frequency energy lasts for 1 s every 5 s, the output energy of each emission of the radio frequency energy is 133J-137J, and according to the different experimental animals, the total energy of the output radio frequency energy is controlled to complete manufacturing of the burn model from the I-degree burn to the III-degree burn of the different experimental animals. According to the method, radio frequency energy with standardized parameters is sent out through radio frequency equipment, so that the experimental animal is burnt, a brand-new animal model burn method is constructed, burn grading is clear, and high repeatability is achieved.

The application discloses a method for establishing a Bama miniature pig spleen deficiency and dampness excess model, and belongs to the technical field of animal models. The method is to reduce the immunity of the body by intraperitoneal injection of cyclophosphamide, and then to stimulate the Bama miniature pig by using high-sugar and high-fat feed and senna leaves in combination with a high-humidity external environment. After 8 weeks, the Bama miniature pig has the clinical manifestations of the spleen deficiency and dampness excess, such as body fatness, fatigue and laziness, white and slippery tongue fur, and loose and watery stool, and the model is verified in the reverse direction by using the classic compound Shenglin Bai Zhusan. The Bama miniature pig spleen deficiency and dampness excess model is applied to the research of human spleen deficiency and dampness excess and the development of spleen-invigorating and dampness-expelling drugs. The model provides a new model for standardizing, standardizing and scientifically evaluating the research of spleen-invigorating and dampness-expelling traditional Chinese medicines, and has the advantages of good practicability, strong conformity, simplicity and objectivity, and conforms to the guidance of the theory of traditional Chinese medicine syndromes, and has a wide application prospect.

The invention relates to the technical field of medicines, in particular to a composition for relieving depression, a preparation and application of the composition. The composition for relieving depression is prepared from the following components in parts by weight: 1 to 3 parts of nicotine and 100 to 5000 parts of imipramine. On a constructed mouse chronic unpredictable stress depression (CUMS) model, depression-like behavioral characteristics of model animals can be remarkably improved by intraperitoneal injection of low dose of nicotine and different doses of imipramine, and the effect is superior to that of a group singly using nicotine and a group singly using imipramine; the effect of rapidly relieving depression-like symptoms of animals can be achieved through the cooperation of low-dose nicotine and imipramine.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

The application discloses an antagonistic bacterium of pathogenic shewanella of Apostichopus japonicus and application thereof, and belongs to the technical field of aquatic microorganisms. Gilvus japonicus The antagonistic bacterium is separated from the intestinal tract of healthy Apostichopus japonicus and is identified as Japanese Yellow Sea Oceanic Bacterium (Shewanella japonica), has no beta-hemolysis characteristic, is safe and non-toxic to Apostichopus japonicus, and can significantly antagonize the pathogenic bacterium Shewanella of Apostichopus japonicus skin rot syndrome. The application also discloses application of the antagonistic bacterium, which can be prepared into an aquatic microecological preparation for preventing and treating the skin rot syndrome of Apostichopus japonicus, and is applied through intraperitoneal injection or immersion, so that the survival rate of Apostichopus japonicus under exposure of the pathogenic bacterium is significantly improved. The strain has strong salt and alkali resistance, tolerances to various antibiotics and chemical drugs, and strong environmental adaptability, can be applied to the cultivation of Apostichopus japonicus to replace traditional antibiotics, effectively solves the problems of food safety and environmental pollution caused by the abuse of antibiotics, and has good industrial application prospect.

The invention belongs to the technical field of biological medicines, and discloses application of AC1903 in preparation of drugs for treating and preventing neutrophil asthma. The invention provides the application of the TRPC5 inhibitor (especially AC1903 or pharmaceutically acceptable salt thereof) in preparation of drugs for preventing and / or treating asthma (especially neutrophil asthma) for the first time. Experiments prove that by intraperitoneal injection of AC1903, the wheezing symptom of a TDI asthma mouse can be remarkably relieved, the airway hyperreactivity, the airway surrounding inflammation level, the total number of inflammatory cells in the airway and the neutrophil count of the TDI asthma mouse are relieved, and secretion of type-2 cytokines and type-17 cytokines of alveolar lavage fluid of the asthma mouse is inhibited. The traditional Chinese medicine composition has a good treatment effect on asthma and has no obvious toxic or side effect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of parinumod in preparation of a medicine for treating biliary atresia. The invention discovers the treatment application of the S100A8 / A9 inhibitor in biliary atresia for the first time. The method comprises the following steps: inducing the formation of BA by intraperitoneal injection of RRV within 24 hours after a BALB / c newborn mouse is born, and after the RRV is injected from the intraperitoneal cavity, from the second day, injecting an S100A8 / A9 inhibitor Paquinimod (dosage: 50 mg / kg) into the intraperitoneal cavity of the mouse once every other day until the twelfth day. It can be observed that the survival time of the BA mouse treated by Paquinimod is prolonged, the jaundice symptom is relieved, the liver function index is obviously improved, and the infiltration number of inflammatory cells around the hepatic bile duct is obviously reduced. The invention provides a new potential target and a treatment strategy for treatment of BA.

The invention discloses a method for researching the action mechanism of saikoside D on paclitaxel-induced peripheral neuropathy, and relates to the technical field of disease mechanism research and drug development. Comprising the following steps: performing continuous administration through intraperitoneal injection of paclitaxel, and establishing a paclitaxel-induced peripheral neuropathy animal model; a von Frey cellosilk experiment and a cold and hot plate experiment are adopted for behavioral detection, and mechanical pain threshold and cold and hot pain sense changes are evaluated; the morphological structure change of the sciatic nerve myelin sheath is observed through Luxol Fast Blue staining; and the expression level of the myelin sheath basic protein in the sciatic nerve is detected by using immunofluorescence staining and Western blotting technologies. According to the invention, a closed-loop research system is formed from animal model construction to molecular mechanism verification; based on behavioral detection, histological analysis and multiple dimensions of a molecular biological technology, the data reliability is ensured, and the curative effect of saikoside D can be comprehensively evaluated.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.